Thermo Fisher & Datavant Partner to Enhance Clinical Research

The global leader in serving science, Thermo Fisher Scientific, has declared a strategic partnership and data collaboration with Datavant, a reliable healthcare data collaboration platform.

This partnership is intended to simplify the relationship between the real-world data (RWD) and clinical research to equip the pharmaceutical and biotechnology firms with the resources to produce more powerful evidence in a shorter period of time.

Under such a joint venture, Thermo Fisher PPD clinical research business and Datavant will facilitate the safe interaction and examination of RWD, including RWD enrichment in randomized clinical trials through PPD CorEvitas Clinical Registries and PPD Evidera systems.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

The privacy-preserving tokenization technology of Datavant enables linking of patient-level data with over 350 real-world data partners and over 80,000 US hospitals and clinics to gain secure and anonymized research datasets.

“Data interoperability is critical to the next generation of evidence generation,” said Karen Kaucic, President of Patient and Advisory Services, and Chief Medical Officer, Clinical Research at Thermo Fisher Scientific. “By enabling privacy-protected data connectivity at scale, this collaboration allows us to deliver a more seamless and efficient research experience for our customers.”

With the support of the encrypted token technology of Datavant incorporated into the infrastructure of Thermo Fisher, the biopharma and biotech companies will enjoy patient data access and more versatile analytics to speed up evidence creation and positively affect patient outcomes.

“This collaboration underscores Datavant’s role in enabling secure, privacy-preserving data connectivity,” added Arnaub Chatterjee, GM and President of Life Sciences at Datavant. The combination of Datavant and Thermo Fisher would facilitate the life sciences partners to produce insights within a shorter timeframe and promote improved outcomes for the patients.